Lung Cancer Screening CT for Firefighters
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Feb 14, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to study the health of firefighters, particularly focusing on their risk for lung cancer and other lung diseases due to their exposure to harmful substances while on the job. The trial will provide chest CT scans to firefighters to check for lung cancer and other cancers that can be spotted through these scans, as well as to identify lung diseases that might increase their cancer risk. Current guidelines mainly consider smoking history, but this study aims to better understand the unique risks that firefighters face.
To participate in this trial, firefighters must be at least 35 years old, have been in the firefighting profession for at least 10 years, and either never smoked or quit more than 15 years ago. They should also be able to understand the study's procedures and consent to participate. Participants will undergo a CT scan and will be monitored throughout the study, which aims to gather vital information to improve cancer screening for firefighters in the future. If you or someone you know meets these criteria and is interested in participating, it could be an important opportunity to contribute to firefighter health research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 35 years or greater. If the participant is above the age of 80, participants must be otherwise healthy and well-fit to undergo treatment if lung cancer were to be discovered.
- • 2. Never smoker or quit more than 15 years ago.
- • 3. Able to understand study procedures and to comply with them for the entire length of the study.
- • 4. Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it.
- • 5. Length in profession for 10 or more years. This includes both volunteer firefighting and professional firefighting, self-attested as verifiable by professional records.
- Additional cases for Aim 2:
- • 1. Age 18+, may include deceased firefighters.
- • 2. A previous or current history of confirmed thoracic malignancy (except localized skin cancer, cancer in situ, or other localized cancers)
- Exclusion Criteria:
- * Aim 1:
- • 1. Contraindication to any study-related procedure or assessment.
- • 2. Personal history of malignancy within 5 years (except localized skin cancer, cancer in situ, or localized cancers that are definitively treated and are unlikely to recur) or lung cancer at any time.
- • 3. Participants will be assessed for active pregnancy per standard procedure for clinical lung cancer screening CT at University of California, San Francisco which includes asking the participants directly along with documentation of whether the negative pregnancy was self-reported or confirmed with a urine pregnancy test.
- • 4. Prior CT chest within 1 year.
- • 5. Symptoms highly suggestive of lung cancer, including unexplained weight loss of over 30 pounds (lbs) within the past 12 months or unexplained hemoptysis.
- * Aim 2:
- • No exclusion criteria
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Jae Ho Sohn, MD, MS
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported